Acute pain

2021 Insights on the Acute Pain Industry - Key Market Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 25, 2021

The "Global Acute Pain Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Acute Pain Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.
  • The research report, Global Acute Pain Epidemiology and Patient Flow Analysis - 2021, provides Acute Pain epidemiology, demographics, and patient flow.
  • The research provides population data to characterize Acute Pain patients, history of the disease at the population level (Acute Pain prevalence, Acute Pain incidence) and at the clinical level (from diagnosis to treated patients).
  • Demographics: Acute Pain patients by age group, gender
    The data from this research will help executives:
    Establish basis for Acute Pain market sizing, assessing market potential, and developing drug forecast models
    Identify Acute Pain patients segments through age groups, gender, and disease sub-types
    Evaluate Acute Pain market opportunities, identify target patient population
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210525005703/en/

ZYUS Life Sciences Receives Notice of Allowance for Canadian Patent Application Covering Pain Management

Retrieved on: 
Tuesday, May 25, 2021

ZYUS Life Sciences Inc. ("ZYUS"), a Canadian-based life sciences company leading scientific research and development in phyto-therapeutics, announced today that it has received a Notice of Allowance from the Canadian Intellectual Property Office (CIPO) for Canadian Patent Application No.

Key Points: 
  • ZYUS Life Sciences Inc. ("ZYUS"), a Canadian-based life sciences company leading scientific research and development in phyto-therapeutics, announced today that it has received a Notice of Allowance from the Canadian Intellectual Property Office (CIPO) for Canadian Patent Application No.
  • The patent covers novel fixed-dose cannabinoid formulations for pain management, including pain due to arthritis, neuropathic pain, injury, accident, surgery, cancer and tissue damage.
  • ZYUS patent application entered the national phase in Canada on December 3, 2020, in conjunction with International Patent Application No.
  • This Notice of Allowance supports ZYUS unwavering commitment to evidence-based research, said ZYUS CEO Brent Zettl.

Nalu Micro-Implantable Pulse Generator Receives Award for Implanted Medical Device Innovation and Health Benefits

Retrieved on: 
Monday, May 24, 2021

The MDEA is a prestigious award that recognizes medical device developers for innovative design, engineering and functionality enhancements that benefit the healthcare system and patients across multiple device categories award levels include bronze, silver and, the top award, gold.

Key Points: 
  • The MDEA is a prestigious award that recognizes medical device developers for innovative design, engineering and functionality enhancements that benefit the healthcare system and patients across multiple device categories award levels include bronze, silver and, the top award, gold.
  • We are a medical technology company focused on developing and commercializing innovative and minimally invasive solutions for patients with chronic neuropathic pain.
  • Our Nalu neurostimulation system, or Nalu system, delivers gentle electrical pulses to the nervous system to modulate pain signals to the brain.
  • Nalu, the Nalu logo and nPower are trademarks of Nalu Medical, Inc.

Global Acute Myocardial Infarction Markets, Epidemiology and Patient Flow Analysis Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, May 24, 2021

The "Global Acute Myocardial Infarction Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Acute Myocardial Infarction Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Global Acute Myocardial Infarction Epidemiology and Patient Flow Analysis - 2021, provides Acute Myocardial Infarction epidemiology, demographics, and patient flow.
  • The research provides population data to characterize Acute Myocardial Infarction patients, history of the disease at the population level (Acute Myocardial Infarction prevalence, Acute Myocardial Infarction incidence) and at the clinical level (from diagnosis to treated patients).
  • Acute Myocardial Infarction patient flow: Acute Myocardial Infarction prevalence, diagnosed, and drug-treated patients
    Demographics: Acute Myocardial Infarction patients by age group, gender
    The data from this research will help executives:
    Establish basis for Acute Myocardial Infarction market sizing, assessing market potential, and developing drug forecast models
    Identify Acute Myocardial Infarction patients segments through age groups, gender, and disease sub-types
    Evaluate Acute Myocardial Infarction market opportunities, identify target patient population
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210524005606/en/

Quick Tube Medical Announces "NEEDLE D" Product Launch

Retrieved on: 
Thursday, May 20, 2021

b'FLETCHER, N.C., May 20, 2021 /PRNewswire-PRWeb/ --Leaders from Quick Tube Medical have just announced that the Company has begun the manufacturing process for a decompression needle kit for use with acute pneumothorax or traumatic arrest.

Key Points: 
  • b'FLETCHER, N.C., May 20, 2021 /PRNewswire-PRWeb/ --Leaders from Quick Tube Medical have just announced that the Company has begun the manufacturing process for a decompression needle kit for use with acute pneumothorax or traumatic arrest.
  • The new product, known as "Needle D," is incision-less, suture-less and includes a locking stabilizer.
  • For more information, visit Quick Tube Medical .
  • Find Quick Tube Medical on LinkedIn .\n'

Electromedical Technologies Announces Upcoming Facebook Live Event with Noted Chiropractor

Retrieved on: 
Wednesday, May 19, 2021

The WellnessProPlus\xc2\xae is an advanced (clinical grade) bioelectronics device designed for the relief of chronic, intractable, acute and post traumatic\xc2\xa0pain.

Key Points: 
  • The WellnessProPlus\xc2\xae is an advanced (clinical grade) bioelectronics device designed for the relief of chronic, intractable, acute and post traumatic\xc2\xa0pain.
  • The WellnessProPlus\xc2\xae uses physics instead of drugs to have an effect on the body.
  • It uses proprietary algorithmic frequencies triggering natural processes in the body to block\xc2\xa0chronic pain.\nMatthew Wolfson, Founder and CEO of Electromedical Technologies, noted, \xe2\x80\x9cWe are pleased to host our first Facebook Live event and thank Dr. Jeff Harper for joining us as our initial, featured guest speaker.
  • Dr. Harper is a highly regarded chiropractor who has a long history of treating chronic pain sufferers along with experience working with EMED\xe2\x80\x99s flagship bioelectronic device, WellnessProPlus\xc2\xae.

Worldwide Flexible & Semi-Rigid Ureteroscopy Industry to 2028 - Featuring Olympus Medical Systems, Hoya and Stryker Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 18, 2021

There has been a high market demand registered for urolithiasis among patients owing to increasing cases of kidney stones among the population.

Key Points: 
  • There has been a high market demand registered for urolithiasis among patients owing to increasing cases of kidney stones among the population.
  • Increasing consumption of fast food and aerated beverages, lack of physical exercise, and changing consumer lifestyle have increased the demand for flexible & semi-rigid ureteroscopy from this segment.\nThe flexible ureteroscopy accounted for a major share of the global market for flexible & semi-rigid ureteroscopy.
  • Market players are introducing advanced and cost-efficient flexible ureteroscopy solutions in the market to offer improved accuracy and effectiveness.
  • Growing cases of kidney-related diseases, changing consumer lifestyles, and the presence of established healthcare infrastructure support market growth in this region.

Just Released! Power-Packed Book, Pursue Real Hope: Discover an Abundant Life Through Your Pain

Retrieved on: 
Tuesday, May 18, 2021

b'COLORADO SPRINGS, Colo., May 18, 2021 /PRNewswire/ -- No one is immune from falling into a hopeless pit of chronic pain, whether physical, mental or emotional.

Key Points: 
  • b'COLORADO SPRINGS, Colo., May 18, 2021 /PRNewswire/ -- No one is immune from falling into a hopeless pit of chronic pain, whether physical, mental or emotional.
  • It can happen at the drop of a hat and linger long enough to impact each and every aspect of life.
  • "This book contains valuable nuggets of wisdom and truth that will inspire those ready to experience the \'new\' within themselves on an undiscovered path of restoration.
  • Pain has a tendency to make people wait.

Gilles Litman, former VP of Digital Health at Sanofi, joins Remedee Labs to accelerate global launch of breakthrough digital health platform focused on chronic pain management

Retrieved on: 
Tuesday, May 18, 2021

I am delighted to join Remedee Labs to help accelerate product offerings and lead international expansion and business development.

Key Points: 
  • I am delighted to join Remedee Labs to help accelerate product offerings and lead international expansion and business development.
  • We have big goals at Remedee Labs, including our primary focus of making our services accessible to as many people as possiblewith chronic pain.
  • "\nAdditionally, Remedee Labs is expanding its range of services to address other chronic pain conditions and has started several clinical trials in endometriosis, osteoarthritis, migraines and cancer pain.
  • His expertise will allow us to speed up the development of our service platform for patients with chronic pain and begin our international expansion.

Gilles Litman, former VP of Digital Health at Sanofi, joins Remedee Labs to accelerate global launch of breakthrough digital health platform focused on chronic pain management

Retrieved on: 
Tuesday, May 18, 2021

I am delighted to join Remedee Labs to help accelerate product offerings and lead international expansion and business development.

Key Points: 
  • I am delighted to join Remedee Labs to help accelerate product offerings and lead international expansion and business development.
  • We have big goals at Remedee Labs, including our primary focus of making our services accessible to as many people as possiblewith chronic pain.
  • "\nAdditionally, Remedee Labs is expanding its range of services to address other chronic pain conditions and has started several clinical trials in endometriosis, osteoarthritis, migraines and cancer pain.
  • His expertise will allow us to speed up the development of our service platform for patients with chronic pain and begin our international expansion.